MARKETS / NASDAQ / RKDA
NASDAQ · CRUDE PETROLEUM & NATURAL GAS · SMALL CAP

Arcadia Biosciences, Inc. RKDA

12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$4.9M
▼ 3.7% vs FY2024
EPS · FY25
$-1.71
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-37.6%
Net margin · FY25
-48.1%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.9M
Revenue, FY2025 · full 12-year series below
Revenue Net income
0.00250.0050.00750.010.0-0.020142017202020232025
0.00250.0050.00750.010.0-0.02016201920222025

The company lost 48 cents on every revenue dollar this year.

Per share
USD -1.71
Diluted EPS, FY2025
EPS
0.40.81.2-1.7120142017202020232025
0.40.81.2-1.712016201920222025

The company pays no cash dividend.

Profitability
-37.6%
Return on equity, FY2025
ROE
0.250.50.751-37.6%20142017202020232025
0.250.50.751-37.6%2016201920222025
Operating margin-51.5%
Net margin-48.1%
Return on assets-23.3%

Each USD of equity lost 38 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
−9.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−13.2%
−9.6%
−1.1%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.00B
Shares outstanding, FY2025
0.000.0020142017202020232025
0.000.002016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 6.5M
total assets, end of FY2025
Total assetsUSD 6.5M
CashUSD 259,000.00
Current ratio3.09×

History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.71
−5.17
−11.29
−25.65
−27.56
−0.47
−4.53
−3.58
−7.28
−8.85
−0.73
−10.71
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−37.6
−73.8
−82.5
−59.0
−49.8
−26.3
−280.8
−129.5
−104.0
−62.9
·
·
Shares out B
0.00
0.00
0.00
0.00
0.00
0.01
0.01
0.00
0.00
0.00
0.04
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
36 of 36
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed